600521.SS
600521.SS
CNE000001DL5
ZHEJIANG HUAHAI PHARMACEUTICAL
Loading chart...

Company Profile

Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services. Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.

Related stocks

000513.SZ
000513.SZ • China
LIVZON GROUP
30.5 CNY
4.05B USD 1Y -21.4%
600566.SS
600566.SS • China
HUBEI JUMPCAN PHARMACEUTICAL CO
26.7 CNY
3.68B USD 1Y +8.3%
000739.SZ
000739.SZ • China
APELOA PHARMA.
25.4 CNY
4.4B USD 1Y +55.9%
600535.SS
600535.SS • China
TASLY PHARMACEUTICAL GROUP CO L
14.2 CNY
3.17B USD 1Y -10.3%
688192.SS
688192.SS • China
DIZAL PHARMACEUTICAL CO LTD
59.95 CNY
4.17B USD 1Y -15%
000423.SZ
000423.SZ • China
DEEJ
46.68 CNY
4.47B USD 1Y -1.3%
000661.SZ
000661.SZ • China
CCHN
71.9 CNY
4.39B USD 1Y -44.4%
002603.SZ
002603.SZ • China
YILING
15.53 CNY
3.88B USD 1Y -4.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
40.5% p.a.
Max Drawdown (5Y)
-57.7%
Sharpe Ratio (5Y)
-0.10
Beta Factor
0.15
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -74.6% in the extended horizon.
ende